ScienceDex / Researcher record
Gary Fanger
- Rise Therapeutics, Llc (no department on record)
From the FY2025 NIH awards this investigator leads as contact PI. The department is the award's.
- Early Career
- Diverse Portfolio
NIH Funding · FY2025
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2024 | $5,683,067 | 7 | #918 |
| 2025 | $2,914,403 | 4 | #3,582 |
| 2026 | $3,069,050 | 4 | #5,981 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20247 records
- FY2025 · selected4 records
- FY20264 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 14958505Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
FY2025 award records by amount
NIH award records listing Gary Fanger as a PI. Multi-PI records show the full award amount for context.
- 5R44AG084484-03R44Contact PIA Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis$953Kaward amount
- 5R44AI174844-03R44Co-investigatorA Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis$827.7Kaward amount
- 5SB1DK141356-02SB1Contact PIA Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis$704.6Kaward amount
- 1UG3DE034134-01A1UG3Contact PIA Novel Immunological-Directed Probiotic for the Treatment of Sjögren’s Syndrome$429.2Kaward amount
Award organization
Organizations that administered FY2025 awards listing Gary Fanger as a PI.
FY2025 award administered by Rise Therapeutics, Llc (MD).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardRise Therapeutics, Llc
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024$2M Cumulative Funding
- 2024$5M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #918
- 2024Entered Top 25% NationallyRanked #918
- 2024Entered Top 10% NationallyRanked #918
- 2024Entered Top 5% NationallyRanked #918
- 2026$10M Cumulative Funding
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Gary Fanger.